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Abstract
Introduction: Cardiac surgery encompasses various stimuli that trigger pro-inflammatory mediators, reactive
oxygen species and mobilization of leucocytes. The aim of this study was to evaluate the effect of xenon on the
inflammatory response during cardiac surgery.
Methods: This randomized trial enrolled 30 patients who underwent elective on-pump coronary-artery bypass
grafting in balanced anaesthesia of either xenon or sevoflurane. For this secondary analysis, blood samples were
drawn prior to the operation, intra-operatively and on the first post-operative day to measure the pro- and anti-
inflammatory cytokines interleukin-6 (IL-6), interleukin-8/C-X-C motif ligand 8 (IL-8/CXCL8), and interleukin-10 (IL-10).
Chemokines such as C-X-C motif ligand 12/ stromal cell-derived factor-1α (CXCL12/SDF-1α) and macrophage
migration inhibitory factor (MIF) were measured to characterize xenon’s perioperative inflammatory profile and its
impact on migration of peripheral blood mononuclear cells (PBMC).
Results: Xenon enhanced the postoperative increase of IL-6 compared to sevoflurane (Xenon: 90.7 versus sevoflurane:
33.7 pg/ml; p = 0.035) and attenuated the increase of IL-10 (Xenon: 127.9 versus sevoflurane: 548.3 pg/ml; p = 0.028). Both
groups demonstrated a comparable intraoperative increase of oxidative stress (intra-OP: p = 0.29; post-OP: p = 0.65). While
both groups showed an intraoperative increase of the cardioprotective mediators MIF and CXCL12/SDF-1α,
only MIF levels decreased in the xenon group on the first postoperative day (50.0 ng/ml compared to 23.3
ng/ml; p = 0.012), whereas it remained elevated after sevoflurane anaesthesia (58.3 ng/ml to 53.6 ng/ml).
Effects of patients’ serum on chemotactic migration of peripheral mononuclear blood cells taken from healthy
volunteers indicated a tendency towards enhanced migration after sevoflurane anaesthesia (p = 0.07).
Conclusions: Compared to sevoflurane, balanced xenon anaesthesia triggers pro-inflammatory effects and
suppresses the anti-inflammatory response in cardiac surgery patients even though the clinical significance
remains unknown.
Trial registration: This clinical trial was approved by the European Medicines Agency (EudraCT-number: 2010-
023942-63) and at ClinicalTrials.gov (NCT01285271; first received: January 24, 2011).
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Introduction
Xenon’s well-known neuro- and cardioprotective proper-
ties render this noble gas an attractive alternative to con-
ventional volatile anaesthetics, which has been intensively
investigated in a variety of experimental and clinical trials
[1–5]. Previous studies controversially discussed xenon’s
effects on the inflammatory response, whereas the under-
lying mechanisms remained elusive [6, 7]. In this context,
de Rossi and co-workers previously demonstrated anti-
inflammatory properties of xenon, which were supposed
to result from increased removal of selectin PSGL-1 and
L-selectin [7]. In addition, xenon was suggested to limit
myocardial and brain injury through inhibition of the
N-methyl-d-aspartate (NMDA) receptor. This is of
particular relevance during excessive activation after is-
chaemia and reperfusion and frequently results in glu-
tamate excitotoxicity [8, 9]. In contrast, only a few
experimental studies have demonstrated xenon’s pro-
inflammatory properties, which have been attributed to
its leucocyte- and platelet-activating properties [6] and/
or influence on Ca2+ homeostasis [5].
The use of cardiopulmonary bypass (CPB) is recognized
as a potent stimulus for the release of inflammatory medi-
ators, reactive oxygen species and mobilization of leuco-
cytes that contribute to cardiac dysfunction [10, 11] and
organ injury [12–14], which is of particular relevance for
patients undergoing cardiac surgery [15]. In this context,
the influence of anaesthetics on the inflammatory
response and oxidative stress has increasingly been con-
sidered [16, 17]. Emerging evidence indicates that xenon
has beneficial effects on global hemodynamic perform-
ance, myocardial contractility and coronary blood flow
[18–21]. In addition previous studies demonstrated that
xenon augments myocardial recovery and limits the extent
of myocardial injury in different animal models, which
may be of particular relevance for patients undergoing
cardiac surgery [22, 23].
To further characterize xenon’s influence on the in-
flammatory response, we performed a secondary analysis
of a recently published randomized controlled trial that
evaluated the safety and feasibility of balanced xenon an-
aesthesia in cardiac surgery patients [24]. As the clinical
data did not support xenon’s superiority compared to
the well-established volatile sevoflurane, we hypothe-
sized that underlying mechanisms may be due to xenon-
induced pro-inflammatory effects.
Materials and methods
Study design and patients
The present study is a predefined secondary analysis of a
randomized, single-blinded, controlled clinical trial ap-
proved by the local institutional review board (Ethics
Committee of the RWTH Aachen University, Faculty of
Medicine, Aachen, Germany; ethic vote: 10–017), the
German Federal Drug Administration (BfArM), and
registered at the European Medicines Agency (EudraCT-
number: 2010-023942-63) and at ClinicalTrials.gov
(NCT01285271). In total, 30 patients scheduled for
elective cardiac surgery with the use of cardiopulmonary
bypass were included in this prospective single-centre
study. Exclusion criteria were emergency operations,
known or suspected pregnancy, patients’ age less than
18 years, and failure to obtain informed consent. Periph-
eral mononuclear blood cells were taken from healthy
volunteers for performance of migration assays (ethic
vote: EK 191/14).
For cardiopulmonary bypass a circuit (Stockert s5, Sorin
Group Germany, Munich, Germany) with moderate
hypothermia (32–34 °C) was used. Antegrade infusion of
cold crystalloid cardioplegic solution (CustodiolTM,
Koehler Chemie, Alsbach-Haehnlein, Germany) in-
duced cardiac arrest. A non-pulsatile pump flow of 2.2
litre min−1 m−2 was used for extracorporeal circulation.
Details of the study were published elsewhere [25]. In
brief, patients were randomized to receive either balanced
anaesthesia using xenon (end-expiratory concentrations of
45–50 % vol) or sevoflurane (end-expiratory concentra-
tions of 1.0–1.4 % volume) each combined with continu-
ous infusion of sufentanil (0.5–1.5 μg kg−1 h−1). To enable
a comparable depth of anaesthesia, continuous monitoring
of the bispectral index (BIS, Convidien, Dublin, Ireland)
was performed in all patients. After surgery, all patients
were transferred to the intensive care unit (ICU) and the
postoperative treatment was standardized according to
our institutional guidelines.
In order to analyse the complex immune response to
xenon and sevoflurane exposure in cardiac surgery
patients we first measured the clinically common cyto-
kine and acute phase protein interleukin-6 (IL-6) as well
as IL-8/CXCL8 and their anti-inflammatory counterpart
IL-10, followed by the analysis of oxidation-reduction
potential (ORP) to account for inflammation-aggravating
effects of oxidative stress. To further investigate the
chemotactic properties of both anaesthetic gases we
measured stromal cell-derived factor-1α (SDF-1α) and
macrophage migration inhibitory factor (MIF), and per-
formed peripheral blood mononuclear cell (PBMC) mi-
gration assays.
Laboratory assessments
In addition to clinical routine measurements, serum sam-
ples from patients were drawn directly before induction of
anaesthesia (pre-OP), immediately before termination of
surgery (intra-OP) and 24 h postoperatively (post-OP).
We measured cytokine concentrations, determined
serum oxidation-reduction potential (ORP) as an indi-
cator of oxidative stress, and investigated serum influ-
ence on the migration of PBMCs. The blood samples
Breuer et al. Critical Care  (2015) 19:365 Page 2 of 10
were immediately centrifuged (3,000 rpm, 10 minutes)
and the supernatant transferred to cryotubes. The
serum samples were subsequently stored at −80 °C until
analysis in 2013 and 2014.
Serum cytokine concentration
Serum concentrations of SDF-1α/CXCL12, IL-6, IL-8/
CXCL8 and IL-10 were determined with commercially avail-
able ELISA assays (CXCL12, IL-6, IL-8, IL-10; R&D Systems,
Wiesbaden-Nordenstadt, Germany) according to the manu-
facturer’s instructions. Serum levels of MIF were assessed
using an ELISA technique as previously described [26], using
capture antibody MAB289 and detection antibody BAF289
(both R&D Systems, Wiesbaden-Nordenstadt, Germany).
Measurement of the oxidation-reduction potential in
serum samples
The measurement of ORP provides a reliable method to
assess the balance between total pro-oxidants and anti-
oxidants in the blood [27]. A higher static ORP is indica-
tive of oxidative stress. Taking into account that cardiac
surgery is a contributing source of oxidative stress [28]
we measured the static ORP of the serum samples as
previously described [29, 30].
Isolation of PBMCs from healthy volunteers for in vitro
culture
All cell culture activity assays were performed under
sterile conditions in a laminar flow hood. The cells were
cultured in a CO2-incubator at 37 °C and 5 % CO2.
Mononuclear cells were obtained from five buffy coats,
which were received from healthy volunteers (n = 5) after
informed consent in accordance with the local ethics
committee (Ethics Committee of the RWTH Aachen
University, Faculty of Medicine, Aachen, Germany; ethic
vote: EK 191/14). The cells were separated by Ficoll dens-
ity gradient centrifugation (GE Healthcare, Chalfont, UK)
and subsequently plated on cell culture dishes (Greiner
Bio-One, Kremsmuenster, Austria) and cultured in
medium (RPMI 1640), enriched with 10 % fetal calf serum,
1 % Penicillin/Streptomycin and 1 % non-essential amino
acids (all from Life Technologies Carlsbad, USA). The
medium was changed after 3 days to remove non-
adherent cells and cells were harvested on day 4.
For detachment of adherent cells prior to migration ex-
periments, the medium was removed and the cells were
washed with phosphate-buffered saline (PBS). Afterwards,
a cell scraper (Corning Inc., Tewksbury, USA) was used to
detach the cells, which were subsequently re-suspended in
RPMI 1640 serum-starved medium containing only 0.5 %
bovine serum albumin (BSA, Roth, Karlsruhe, Germany).
The cells were washed with PBS and finally, the solution
was centrifuged for 15 minutes at 1,250 rpm and the pellet
was re-suspended in RPMI 1640 serum-starved medium
containing 0.5 % BSA (serum-starved medium, Sigma
Aldrich, St. Louis, MO, USA).
PBMC migration assays
In order to reveal the influence of different chemokines
within the serum samples on inflammatory cells, PBMC
migration assays were performed using a Transwell
chamber (Corning Inc., Tewksbury, USA) in a 96-well
plate format and cell culture inserts containing filters
with a pore-size of 5 μm (Corning Inc., Tewksbury,
USA). The cells were detached as described above and
counted. For the migration assay, 50.000 cells per well
(in 75 μl medium) were used. Lower chambers contained
serum samples (1:5 dilution) in RPMI 1640 medium
containing 0.5 % BSA. PBMCs in the same medium were
placed into the upper chamber of each well.
A second migration assay was performed to investigate
the effect of immunosuppressive factors within the serum
samples. PBMCs were first divided into Eppendorf tubes,
each containing one serum sample (1:2 dilution with
RPMI 1640 serum-starved medium) and incubated for 6
h. Subsequently, the serum samples were further diluted
(1:5) and 50.000 cells of each Eppendorf tube were seeded
into one migration chamber. Afterwards, all cells were
allowed to migrate towards 100 ng/ml recombinant MCP-
1 (Peprotech, Rocky Hill, USA).
In both cases, after three hours of migration at 37 °C
and 5 % CO2, all cell culture inserts were removed. To
optimize the counting conditions, migrated cells were
fixed and stained with Hoechst dye (ImmunoChemistry
Technologies, LLC, Bloomington, USA) diluted in 3.6 %
paraformaldehyde (PFA) (1:1000). Finally, the fixed cells
were incubated overnight.
Pictures were taken under a microscope (×100 mag-
nification) the next morning and migrated cells were
counted by an independent team member blinded to
the study using the semi-automated software ImageJ
(National Institutes of Health, Maryland, USA). Apart
from diminishing the background and optimizing count-
ing conditions, the software allows marking of the cells
and adds them automatically onto a tally sheet. To guar-
antee that counting conditions were the same in each in-
dividual experiment, pictures were taken of the same
position within the migration chambers in each individual
experiment.
Statistical analysis
All data were statistically analysed using a commercially
available software package (GraphPad Prism 6.0, Graph-
pad Software Inc., San Diego, CA, USA; SPSS 21, IBM,
USA). All data were tested for normal distribution with
the Shapiro–Wilk’s test. Given the explorative nature of
this pre-planned post-hoc analysis, normally distributed
data from single measurements were compared between
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the groups at single time points using Student’s t test
(two groups), which was adjusted for multiple measure-
ments, in accordance with our statistician’s advice. Non-
parametric single measurements were compared using
the Mann–Whitney U test. Proportions were compared
using the Chi-square test. In all cases, a level of p <0.05
was considered statistically significant.
Results
Baseline characteristics
Baseline characteristics of enrolled patients are reported
elsewhere [24]. No significant differences between the
groups were detected prior to surgery and patients in-
cluded reflect a representative cohort of cardiac surgery
patients. The time course of BIS values was comparable
between both groups during the entire observation period.
Xenon stimulates the perioperative increase in IL-6, but
not IL-8, IL-10 and oxidative stress
To characterize the influence of xenon versus sevoflurane
on the inflammatory response, we measured serum levels
of well-known inflammatory cytokines and oxidative stress
perioperatively. Circulating levels of IL-6 decreased signifi-
cantly in the xenon group compared to the sevoflurane
group after the end of surgery (xenon (Xe) 90.7 pg/ml vs.
sevoflurane (Sev) 33.7 pg/ml; p = 0.035, Fig. 1a). In con-
trast, we did not find any significant differences in IL-8
release between both groups during the entire observation
period (Fig. 1b). In terms of the anti-inflammatory
response, serum levels of IL-10 increased continuously in
the sevoflurane group, whereas there were no major
changes in levels of IL-10 after xenon exposure (127.9 vs.
548.3 pg/ml; p = 0.028, Fig. 1c). As oxidative stress, is
known to amplify the perioperative immune response
[31], redox balance was assessed in the included patients.
No significant differences in oxidative stress were detected
between the groups during the study (Additional file 1).
Xenon reduces the postoperative serum levels of MIF but
does not affect perioperative serum levels of SDF-1α
Recent data indicate a cardioprotective role during acute
myocardial ischaemia/reperfusion [32, 33] and in pa-
tients undergoing cardiac surgery [25, 26]. Therefore we
compared the perioperative profile of MIF and demon-
strated a significant intraoperative increase in MIF in
both groups, whereas serum levels in the xenon group
were significantly lower on the first postoperative day in
comparison to the sevoflurane group (Xe 23.3 pg/ml vs.
Sev 53.6 pg/ml; p = 0.012; Fig. 2b).
SDF-1α is crucially involved in trafficking of immune
cells during inflammation. We therefore analysed circu-
lating levels of SDF-1α. Serum levels did not differ sig-
nificantly between the groups during the intervention
(p = 0.157, Fig. 2a).
Xenon does not facilitate the chemotactic migration of
peripheral blood mononuclear cells (PBMCs)
In extension, we investigated potential anaesthesia-
induced effects on the recruitment of immune cells, which
are known to further enhance pro-inflammatory responses
after myocardial ischaemia. Serum samples taken intraop-
eratively or postoperatively from the xenon group did not
influence PBMC migration when compared to the effect
of preoperatively drawn serum samples as control. In con-
trast, serum samples from patients treated with sevoflur-
ane triggered a measurable increase in the chemotactic
response of PBMCs (Fig. 3a).
Aesthetics may not only directly lead to the release of
pro-chemotactic molecules but may also indirectly affect
the migratory behaviour of circulating inflammatory cells,
including contributions to chemokinetic effects. To study
such a potential influence on circulating inflammatory
cells in the blood of cardiac surgery patients, PBMCs from
healthy volunteers were pre-incubated with randomly se-
lected anaesthetic-conditioned serum samples from both
groups to mimic effects on chemokinesis, e.g., activation
or downregulation or migration-competent receptors, or
desensitization of signalling pathways. Afterwards, a
chemotaxis assay was performed with the PBMCs sub-
jected to a chemotactic gradient of recombinant MCP-1/
CCL-2 placed in the lower chamber of the migration de-
vice. Sevoflurane-preconditioned PBMCs trended towards
elevated migration activity, whereas PBMC pre-treatment
with xenon-conditioning postoperatively had no effect at
all on migration behaviour (Fig. 3b). Together, while not
statistically significant at p <0.05, these findings indicated
that sevoflurane promotes the migration of circulating
mononuclear cells by both chemotactic and chemokinetic
mechanisms.
Significance of xenon anaesthesia in relation to outcome
of patients
For the clinical significance of xenon in terms of outcome,
there were no significant differences between the two
interventional groups, as has already been reported in
more detail elsewhere [24].
Discussion
The present study is the first that highlights the influ-
ence of xenon anaesthesia on the inflammatory re-
sponse in patients undergoing cardiac surgery. Our
data demonstrate that balanced xenon anaesthesia trig-
gers pro-inflammatory effects and suppresses the anti-
inflammatory response compared to the well-known
anaesthetic, sevoflurane, in the complex clinical setting
of cardiac surgery.
Recently, the first randomized controlled trial demon-
strated the feasibility and safety of balanced xenon anaes-
thesia for cardiac surgery [24]. In terms of the significance
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of xenon in relation to clinical outcome, previous data did
not confirm the hypothesis that xenon may represent
superior characteristics compared to the well-known
anaesthetic, sevoflurane, and the underlying mechanisms
remained unknown. As the inflammatory response is
widely known to determine the extent of organ
Fig. 1 Perioperative time course of interleukin (IL)-6 (IL-6) (a), IL-8 (b) and IL-10 (c). Circulating serum levels of IL-6, IL-8, and IL-10 were measured
perioperatively in serum samples of patients who underwent cardiac surgery. Values are depicted in pg/ml. IL-6, IL-8 and IL-10 increased during
the surgical intervention. While IL-6 levels increased postoperatively in the xenon group compared to the sevoflurane group, IL-10 levels only
increased significantly in the sevoflurane group during surgery. Serum levels of IL-8 levels did not differ between both groups during the observation.
Data are shown as boxplots with means and maximal to minimal values (p values are indicated within the figure). Pre-OP baseline, before induction of
anaesthesia, intra-op immediately before termination of surgery, post-OP 24 h after surgery
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dysfunction after surgery, we compared the inflammatory
profile between patients after balanced xenon or sevoflur-
ane anaesthesia. Interestingly, we found significantly
higher IL-6 levels after xenon anaesthesia and the intraop-
erative release of anti-inflammatory IL-10 was significantly
reduced in cardiac surgery patients when compared to
sevoflurane. While knowledge about xenon-induced
effects on the inflammatory response during cardiac sur-
gery is limited to experimental data, Kawamura and co-
workers demonstrated that sevoflurane is able to suppress
the production of IL-6, but not IL-10 [34]. Furthermore, it
was shown that the addition of sevoflurane to blood cardi-
oplegia resulted in a reduced activity of neutrophils [35],
thereby showing an anti-inflammatory effect [36].
In addition to these well-known cytokines, we measured
serum levels of the pleiotropic cytokine MIF, which has
chemokine-like functions and recently was demonstrated
to provide cardioprotective effects during acute myocar-
dial ischaemia/reperfusion [32, 33]. MIF serum concentra-
tions showed a comparable intraoperative increase in both
groups, whereas MIF levels remained significantly elevated
in patients after sevoflurane anaesthesia until the 1st
Fig. 2 a Perioperative time course of CXCL12/stromal cell-derived factor 1α (SDF-1α) serum concentrations. Measurement of CXCL12/SDF-1α levels
in the serum of patients who underwent cardiac surgery. Values are depicted in pg/ml. CXCL12 levels increased in both groups during surgical
intervention. However, there were no significant differences between groups. Shown as boxplots with means and maximal to minimal values
(p values are indicated). Pre-OP baseline, before induction of anaesthesia, intra-op immediately before termination of surgery, post-OP 24 h after
surgery. b Perioperative time course of macrophage migration inhibitory factor (MIF) serum concentrations. The measurement of perioperative
circulating MIF levels in cardiac surgery patients was performed as described previously [25]. Values are depicted in ng/ml. There was a strong
intraoperative increase in serum MIF levels in both groups, which decreased again postoperatively. Postoperative measured MIF levels were
significantly reduced after xenon anaesthesia compared to sevoflurane. Data are shown as interleaved boxes with means and maximal to
minimal values (p values are indicated)
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postoperative day. As previous studies reported on the
anti-inflammatory and thus, organoprotective effects of
MIF during cardiac surgery [25, 26], it remains speculative
whether the significantly decreased MIF levels in the
xenon group may reduce the defence mechanisms in car-
diac surgery patients compared to sevoflurane.
In view of the diverging inflammatory response, we next
investigated the overall effect of patients’ serum samples, in-
cluding the highly complex cytokine cocktail, on migration
of immune cells. We found a tendency of a higher migra-
tion of PBMCs towards serum samples obtained from
sevoflurane-treated patients compared to xenon. In vivo,
migration of PBMCs is crucial for clearance of dead cells,
tissues and subsequent regeneration. In this context, signifi-
cant suppression of post-ischaemic inflammation is associ-
ated with detrimental consequences [37]. Therefore, the
reduced migration of PBMCs in the xenon group may
significantly affect the essential repair mechanisms after
cardiac surgery.
To identify the potential key players for recruitment of
PBMCs in both groups we measured serum levels of IL-
8 and SDF-1, which are well-known chemokines in the
inflammatory response for the trafficking of immune
cells to the damaged tissue [38, 39]. Of note, recent
studies indicate that SDF-1α provides pro-inflammatory
properties, which may turn to anti-inflammatory func-
tion after leukocyte invasion [40]. However, we did not
find any significant differences in the perioperative pro-
file of SDF-1α or IL-8 levels between xenon and sevo-
flurane exposure, indicating that (non-classical) factors
other than SDF-1α or IL-8 may be responsible for the
post-ischaemic recruitment of PBMCs. In this context
recent data demonstrate that the effect of SDF is abol-
ished by heparin, both on the chemokine and receptor
Fig. 3 Migration assay of peripheral blood mononuclear cells (PBMCs) in serum samples of cardiac surgery patients after xenon or sevoflurane
anaesthesia. a In vitro migration of PBMCs is increased by serum samples of patients after sevoflurane anaesthesia. Extent of PBMC migration
(received from healthy volunteers) towards serum samples from cardiac surgery patients is demonstrated in both groups. While PBMC migration
towards serum samples was increased during surgery in the sevoflurane group, PBMC migration was not affected in serum samples from the
xenon group. Data are shown in boxplots with means and maximal to minimal values (p values are indicated). Pre-OP baseline, before induction
of anaesthesia, intra-op immediately before termination of surgery, post-OP 24 h after surgery. b Serum samples from patients after xenon
anaesthesia show no chemokinetic effect on PBMCs. Migration of PBMCs from healthy volunteers, which were pre-incubated in serum samples
elicited by recombinant CCL2/monocyte chemoattractant protein-1 (MCP-1), is demonstrated. No significant difference was measured between
the groups during surgery. Data are shown as boxplots with means and maximal to minimal values (p values are indicated)
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side of the signalling pathway [41]. As cardiac surgery
patients receive high-dose heparin intraoperatively this
effect may significantly influence the effect on migration
of PBMCs in the present study.
Last, we compared the extent of oxidative stress by
measurement of the redox balance in both treatment
groups. Oxidative stress may lead to myocardial injury
after reperfusion [42]. However, the extent of oxidative
stress measured by ORP did not reveal any significant dif-
ferences between xenon and sevoflurane exposure, indi-
cating that neither sevoflurane nor xenon is able to
significantly reduce the well-known intraoperative in-
crease in oxidative stress [43, 44].
The present findings are in apparent contrast to previ-
ous results, which showed comparable effects on the
immune system after xenon or sevoflurane anaesthesia
in patients during general abdominal surgery [45]. How-
ever, these contrary findings should be considered cau-
tiously in the light of different clinical settings, which
are characterized by a significantly different inflamma-
tory profile. While general surgery is known to stimulate
only a mild systemic immune response, cardiac surgery
frequently triggers an overwhelming perioperative im-
mune reaction that frequently leads to the development
of postoperative organ dysfunction [46].
Limitations
We acknowledge that the present sub-study has several
limitations, which may mitigate the significance of the
present findings. First, this study was performed in a
small patient cohort and therefore may not be ad-
equately powered for the measurements performed.
Therefore, we concede that the present data should be
interpreted cautiously. However, the presented findings
were received from a randomized, single-blinded, con-
trolled clinical trial and thus, may be considered
hypothesis-generating.
Second, we realize that the present analysis only
focused on cytokines and chemokines, which were con-
sidered as most likely to be crucially involved in inflam-
matory response, with significance in relation to the
clinical outcome of patients. Due to the limited quantity
of serum samples we had to focus on a panel of crucial
mediators. Additional analyses are encouraged to pro-
vide further insight into in vivo mechanisms induced by
xenon, to enable a more comprehensive understanding
of the effects of xenon and the frequently observed
discrepancy between experimental and clinical studies
[6, 7, 47].
Third, as sevoflurane is known to have cardioprotec-
tive properties, we assume that comparison to an anaes-
thetic with neutral effects would have been desirable.
However neither propofol nor an alternative volatile an-
aesthetic would comply with these requirements. Last, the
absolute serum levels should be interpreted cautiously, as
storage might have influenced the detection of cytokine
levels. However, duration of storage did not differ between
the treatment groups.
Furthermore, it remains elusive whether xenon aggra-
vates the pro-inflammatory response or whether the me-
diated effects of xenon are inferior to the well-known
properties of sevoflurane in the setting of cardiac sur-
gery. We presume that the pro-inflammatory properties
of xenon may have counterbalanced its well-known
promising effects, which have been repeatedly demon-
strated in the past [1–5].
Conclusion
The present study demonstrates that balanced xenon
anaesthesia aggravates the inflammatory response and
increases the intraoperative release of the pro-
inflammatory cytokine IL-6, whereas the secretion of
anti-inflammatory cytokines IL-10 and MIF was sup-
pressed during cardiac surgery in comparison to sevo-
flurane. Additional large-scale prospective studies are
needed to evaluate the role of xenon as a potential
alternative to sevoflurane in the setting of cardiac
surgery.
Key messages
 Balanced xenon anaesthesia aggravates the
inflammatory response in cardiac surgery patients
 Xenon stimulates the intraoperative release of the
pro-inflammatory cytokine IL-6 but not IL-8
 Xenon suppresses the increase of anti-inflammatory
cytokines IL-10 and MIF during cardiac surgery
 Compared to the well-established anaesthetic
sevoflurane, xenon does not alter intraoperatively
measured oxidative stress
 Xenon does not facilitate the well-known
chemotactic migration of PBMCs during cardiac
surgery
Additional file
Additional file 1: Measurement of intra- and postoperative redox
balance. The intra- and postoperative redox balance was measured by static
oxidation-reduction potential (ORP) in the serum samples and given in milli-
volts (mV). On comparison the xenon and sevoflurane groups had a compar-
able time course for ORP, indicating that both anaesthetics have the same
influence on oxidative stress in cardiac surgery patients. Data are mean values
± SD. Pre-OP baseline, before induction of anaesthesia, intra-op immediately
before termination of surgery, post-OP 24 h after surgery. (PDF 39 kb)
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